Subscribe
Topline results from the phase 3b trial revealed significant improvements in patients with skin of color whose psoriasis was treated with guselkumab.
FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis
Arcutis Presents Positive Roflumilast Foam Data From ARRECTOR Trial in Scalp and Body PsO at EADV
Interim Data From Almirall's POSITIVE Study Reveals Significant Well-Being Improvements Among Psoriasis Patients
Bristol Myers Squibb Presents 3-Year Safety and Efficacy Data of Deucravacitinib for PsO at EADV
Joseph Gorelick, MSN, FNP-C
Brad P. Glick, DO, MPH, FAAD
Hilary Baldwin; Neal Bhatia, MD
Tina Bhutani, MD
June 17-19, 2026
Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD
Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc
Andrew Alexis, MD, MPH; Leon Kircik, MD
Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD
Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD